Haselmeier Announces the CE Mark for JuniorSTAR? Half-Unit Insulin Pen
![](/46/pdcnewsitem/03/27/36/E3lMN55XoJOiimP.png)
Haselmeier has announced the CE Mark of JuniorSTAR by Sanofi. JuniorSTAR is a new easy-to-use, half-unit insulin reusable pen that can be used with Lantus (insulin glargine), Apidra (insulin glulisine) or Insuman (recombinant human insulin).
Developed and manufactured by Haselmeier, JuniorSTAR is a light-weight reusable pen with a large dose display, single-step dial back without insulin leakage and delivers from 1 to 30 units per injection.
“Haselmeier is proud to partner with Sanofi on this important programme to develop and manufacture JuniorSTAR and we look forward to continuing our business relationship in the future,” said Frédéric Gabriel, General Manager of Haselmeier.
Director Project Management at Haselmeier, Sandra de Haan adds that “the excellent cooperation between Sanofi and Haselmeier project teams ensured announcement to the diabetes community at the recent EASD congress".
Half-unit dose increment pens provide flexibility to achieve target insulin doses especially in young patients with diabetes. JuniorSTAR has been tested by people with type 1 diabetes (6–18 years old), parents and nurses in a non-comparative survey with 167 insulin pen users from five European countries1:
• 81% of patients/parents and 86% of nurses agreed it is easy to carry on a daily basis, because of its light weight (~ 34 g)
• 98% of patients/parents and 94% of nurses agreed it is easy to read becasue of its large dose display and legible numbers
• 91% of patients/parents and 89% of nurses agreed that the dialling back was easy because of its single-step dial back without insulin leakage
• 93% of survey participants agreed on its ease of use.
JuniorSTAR meets the new ISO 11608-1:2012 standard and passed all requirements for robustness and dose accuracy. It is offered in three different colors (blue, red and silver), for flexibility and insulin differentiation.
JuniorSTAR is expected to be available in Europe and Canada throughout 2014.
Reference
1. D. Klonoff et al., "Evaluation of the JuniorSTAR half-unit insulin pen in young people with type 1 diabetes - user perspectives," European Endocrinology, 9(2), 82–85 (2013).
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance